Cunha, RN;
Aguiar, R;
Cardoso Farinha, FM;
(2018)
Impact of Pegloticase on Patient Outcomes in Refractory Gout: Current Perspectives.
[Review].
Open Access Rheumatology : Research and Reviews
, 10
pp. 141-149.
10.2147/OARRR.S176951.
Preview |
Text
oarrr-176951-impact-of-pegloticase-on-patient-outcomes-in-refractory-gout-101718.pdf - Published Version Download (186kB) | Preview |
Abstract
Gout is currently the most frequent cause of inflammatory arthritis worldwide and is responsible for poor health-related quality of life and loss of work productivity. It is caused by high levels of serum urate, leading to the deposition of monosodium urate crystals in joints and soft tissues. This condition is associated with acute flares and, if untreated or refractory, chronic and potentially destructive arthritis and tophi formation. Pegloticase is a recombinant, pegylated uricase used in the treatment of gout patients who fail conventional urate-lowering therapy. In this review, we discuss the impact of pegloticase on patient outcomes in refractory gout. We analyze different parameters, such as plasma uric acid concentration, frequency of flares, tophi reduction, pain, function, quality of life, and safety.
| Type: | Article |
|---|---|
| Title: | Impact of Pegloticase on Patient Outcomes in Refractory Gout: Current Perspectives |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2147/OARRR.S176951 |
| Publisher version: | https://doi.org/10.2147/OARRR.S176951 |
| Language: | English |
| Additional information: | This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. |
| Keywords: | gout, urate-lowering therapy, pegloticase, patient outcomes |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10060228 |
Archive Staff Only
 |
View Item |
